MSB to dispute FDA finding in Type A meeting, page-231

JBSINC4 hours ago

WHAT MESO needs to done at the typeA meeting is that they need to bring patients and parents of children to testify and show FDA that it gives a chance or cure or better. That's what SRPT has done back in year 2016, even AdComm voted against the SRPT's DMD for insufficient evidences, and follow by FDA comment, they will not approve any drug without enough evidences regarding the approval with SRPT, that is what FDA actually said. But on the date of PDUFA, FDA approved, prior to this decision, the chief FDA resigned who was strongly against the SRPT. Is that an awkward ? SRPT price? was cut in half, when voted against, $21->> $11, and over $150 now, that f*#$#4 FDA !!! I had to sold all my shares due to FDA's comment and ADcom voted against. If FDA hadn't said a word, I would have held it til the day, the voted was only 3:4? 8:9? something.

Less